Application of data mining and visualization techniques for the prediction of drug-induced nausea in man.

The therapeutic value of many drugs can be limited by gastrointestinal (GI) adverse effects such as nausea and vomiting. Nausea is a subjective human sensation, hence little is known about preclinical biomarkers that may accurately and effectively predict its presence in man. The aim of this analysis was to use informatics and data-mining tools to identify plausible preclinical GI effects that may be associated with nausea and that could be of potential use in its prediction. A total of 86 marketed drugs were used in this analysis, and the main outcome was a confirmation that nausogenic and non-nausogenic drugs can be clearly separated based on their preclinical GI observations. Specifically, combinations of common preclinical GI effects (vomiting, diarrhea, and salivary hypersecretion) proved to be strong predictors. The model was subsequently validated with a subset of 20 blinded proprietary small molecules and successfully predicted clinical outcome in 90% of cases. This investigation demonstrated the feasibility of data-mining approaches to facilitate discovery of novel, plausible associations that can be used to understand drug-induced adverse effects.

[1]  G. Gintant,et al.  Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward. , 2005, Current opinion in chemical biology.

[2]  J. Valentin,et al.  A potential algorithm for predicting drug-induced nausea in man , 2011 .

[3]  S. Vožeh.  The international conference on harmonisation , 2004, European Journal of Clinical Pharmacology.

[4]  P. Vittoz.  Man , 1962, Bloom.

[5]  P. Andrews,et al.  Opportunities for the replacement of animals in the study of nausea and vomiting , 2009, British journal of pharmacology.

[6]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[7]  R. Gama,et al.  Mechanism of glucagon‐induced nausea , 1999, Clinical endocrinology.

[8]  S. Woods,et al.  The Role of CNS Glucagon-Like Peptide-1 (7-36) Amide Receptors in Mediating the Visceral Illness Effects of Lithium Chloride , 2000, The Journal of Neuroscience.

[9]  G. Morrow,et al.  Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics , 1998, Supportive Care in Cancer.

[10]  M. Catalano,et al.  A prospective, double-blind trial of somatostatin analog (octreotide) versus glucagon for the inhibition of small intestinal motility during endoscopic retrograde cholangiopancreatography. , 1995, Gastrointestinal endoscopy.

[11]  S. Sarna,et al.  Pharyngeal, esophageal, and proximal gastric responses associated with vomiting. , 1993, The American journal of physiology.

[12]  D. McTavish,et al.  Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. , 1993, Drugs.

[13]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[14]  A. Robichaud,et al.  Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ). , 2000, Journal of medicinal chemistry.

[15]  L. Grélot,et al.  Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist , 1998, British journal of pharmacology.

[16]  J. Holst,et al.  An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future , 2011, Diabetes, obesity & metabolism.

[17]  R. Mechoulam,et al.  Cannabidiol, a non‐psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats , 2002, Neuroreport.

[18]  H. Kuwano,et al.  Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon , 1998, Journal of Gastroenterology.

[19]  P. Andrews,et al.  The effect of the NK1 receptor antagonist CP-99,994 on emesis and c-fos protein induction by loperamide in the ferret , 2000, Neuropharmacology.

[20]  J J DeGeorge,et al.  Changes to ICH Guideline M3: New and Revised Guidance on Nonclinical Safety Studies to Support Human Clinical Trials and Marketing Authorization , 2011, Clinical pharmacology and therapeutics.

[21]  K. Ossenkopp,et al.  Exposure to a context previously associated with nausea elicits conditioned gaping in rats: A model of anticipatory nausea , 2008, Behavioural Brain Research.

[22]  Matthew Clark,et al.  Fragment-Based Prediction of the Clinical Occurrence of Long QT Syndrome and Torsade de Pointes , 2009, J. Chem. Inf. Model..

[23]  J. Mattsson,et al.  Radiation-induced emesis in monkeys. , 1980, Radiation research.

[24]  M. Pierce.  Transdermal delivery of sumatriptan for the treatment of acute migraine , 2010, Neurotherapeutics.